PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Health

An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist : Short Wave

A small Adelaide University sheep study found a single dose of semaglutide cut maternal cardiac output and fetal oxygen levels within two hours, raising new questions about GLP-1 drug safety during pregnancy.

13sources
13articles
12velocity
+319%since first seen
7d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📍 How it ended

The discussion centered on emerging safety questions, fertility impacts, and the need for greater public awareness, but no definitive conclusions or regulatory actions were reported. The story quieted without a clear resolution in the coverage.

Epilogue added 1d ago, after coverage quieted.

The brief

Adelaide University researchers reported that a single 0.75 mg dose of semaglutide — the active ingredient in Ozempic and Wegovy — significantly reduced maternal cardiac output, uterine blood flow, and fetal arterial oxygen pressure in seven pregnant ewes studied at 117–119 days of gestation. Using phase-contrast MRI and surgically placed catheters, they measured a drop in maternal cardiac output of 0.80 liters per minute at two hours post-infusion, while fetal arterial oxygen pressure fell from 23.25 mmHg at baseline to 18.82 mmHg at two hours. Blood pressure and heart rates remained steady in both mothers and fetuses, and uterine blood flow declined in proportion to the overall reduction in cardiac output. The findings were presented as a conference abstract in the journal Heart, Lung and Circulation.

Study co-author Mitchell Lock said, "Within two hours of administering semaglutide, we found that the amount of blood pumped by the mother's heart had significantly decreased, reducing blood flow to the uterus and lowering oxygen levels in the developing fetus." He added, "Oxygen is essential for healthy fetal growth and development, so any reduction in its supply raises questions about what might happen if exposure to the drug continues throughout pregnancy." Senior researcher Janna Morrison emphasized the findings are preliminary: "Our findings suggest a potential risk to fetal development, but we haven't yet established whether these short-term changes affect fetal growth, what happens over a longer period of semaglutide use or whether similar effects could occur in human pregnancies."

Product labeling advises stopping semaglutide at least two months before a planned pregnancy, but researchers noted many pregnancies are unplanned. A 2025 KFF poll found 12% of U.S. adults were currently taking a GLP-1 medication for weight loss or other health conditions, and in Australia around half a million people take them for diabetes alone, with off-label weight-loss use likely pushing the number higher. Lock said some women may be reluctant to stop because they don't want to regain weight, while others taking the drug for diabetes may worry about destabilizing blood sugar management. Human pregnancy studies have not established a consistent increase in major birth defects following semaglutide exposure, but the available evidence remains limited.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 4d ago.

Quick answers

What did the Adelaide University sheep study find about semaglutide and fetal oxygen levels?

A single 0.75 mg dose of semaglutide given to seven pregnant ewes reduced maternal cardiac output by 0.80 liters per minute and lowered fetal arterial oxygen pressure from 23.25 mmHg at baseline to 18.82 mmHg at two hours, while uterine blood flow fell in proportion to the drop in cardiac output.

Is semaglutide recommended during pregnancy?

No. Product labeling advises stopping semaglutide at least two months before a planned pregnancy, and the drug is not recommended during pregnancy.

Have human studies shown birth defects from semaglutide exposure during pregnancy?

Human pregnancy studies have not established a consistent increase in major birth defects following semaglutide exposure, but the available evidence remains limited.

Coverage (13)

Topics

Related trends

▲ Peaking Business

The GLP-1 boom has a dark side

The FDA orders eye risk warnings on GLP-1 medications like Ozempic and Zepbound, prompting expert guidance.

5 sources 5 articles v 14 6h ago
\n \n \n \n \n \n \n